2012-07-232012-07-232010-08-02PEREIRA Cynthia Mara Brito Lins. Expressão dos genes C-MYC, HER-2 e receptores hormonais como preditores de resposta à quimioterapia neoadjuvante em câncer mamário. 2010. 71 f. Dissertação (Mestrado) - Universidade Federal do Pará, Instituto de Ciências Biológicas, Belém, 2010. Programa de Pós-Graduação em Neurociências e Biologia Celular.https://repositorio.ufpa.br/handle/2011/2859Breast cancer is a higher incidence of tumors in women, and therefore many studies have been performed since the assessment of the epidemiological characteristics, the dynamics biocelular and treatment of this disease. In evaluating responses to treatment, the risk factors are markers that help in choosing the best drug to use. This work aimed to evaluate the genes of estrogen and progesterone receptors, HER-2 and C-MYC in locally advanced breast tumors as predictors of response to neoadjuvant chemotherapy. We studied fragments of mammary malignancy in 50 patients with infiltrating ductal carcinoma, with clinical stage III and E-treated with neoadjuvant chemotherapy. We used the techniques of immunohistochemistry and fluorescence in situ hybridization (FISH). The analysis of hormone receptors showed no statistically significant difference comparing patients with satisfactory response to chemotherapy, the poor and the analysis of HER-2 showed significance only for satisfactory answers, where there was poor amplification of this gene. Regarding C-MYC was observed a statistically significant difference comparing the high amplification of this gene to a poor response to chemotherapy. The study concluded that the C-MYC gene may be an important marker for predicting the treatments used in neoadjuvant chemotherapy for breast cancer.porAcesso AbertoNeoplasias da mamaQuimioterapiaGenes MycGenes erbB-2Marcadores biológicosDissertaçãoCNPQ::CIENCIAS BIOLOGICAS::GENETICA::GENETICA HUMANA E MEDICA